Asian Journal of Medical and Pharmaceutical Researches

5

Authors: Noor Mohammad Noori, Shahrokh Rajaei, Alireza Teimouri, Salma Naderi and Saeed Hashemi

Patent ductus arteriosus accounts for about 10% of congenital heart disease. Although surgical or catheter closure of patent ductus arteriosus is safe but with some complications and not possible in anywhere. Efficacy of ibuprofen for patent ductus arteriosus closure is shown in preterm neonates. The aim of the current study was to evaluate the efficacy and safety of oral ibuprofen in full- term neonates after the first days of life. This study was a randomized clinical trial on 20-28-day term infants with confirmed patent ductus arteriosus. The sample size was 40 infants divided randomly in case (n = 20) and control group (n = 20). The case group received ibuprofen suspension initially with a dosage of 10 mg/kg, then two 5 mg/kg doses 12 hours apart. If ductal closure did not occur, a second course was repeated after one week. Case group was assessed by adverse effects and complications. The control group received no medication or placebo. To confirm patent ductus arteriosus, diagnosis and follow up by 2 dimensional color Doppler echocardiography was performed. Data was analyzed using SPSS version 16 software. There was no significant difference between the two groups in age, weight, sex, and patent ductus arteriosus size. There wasn’t any ductal closure in case group after one course of treatment. Patent ductus arteriosus was closed in 75% of patients in treated group after second course, but no spontaneous closure was reported in control group (P<0.001). None of the patients reported drug complication. The current study indicated that two courses of treatment by oral ibuprofen seem effective with no complications in closing patent ductus arteriosus of full-term infants' aged 20-28 days. However, further research in this field is recommended.

7

Authors: Fariba Karimi1 and Gholamhossein Ranjbar Omrani2

Diabetes mellitus is one of the most common chronic disorders in the world. Previous investigations have suggested that metformin, as a key treatment option in type 2 diabetes, may lead to hyperhomocysteinemia through decreasing the levels of vitamin B12 and folic acid. In this clinical trial, 55 patients with type 2 diabetes who referred to two clinics of Shiraz University of Medical Sciences participated. At first, the participants followed diet regimen alone for 3 months and then in the next 3 months they were treated by metformin. Serum levels of vitamin B12, folic acid and homocysteine were checked before and after the diet alone and metformin consumption, then they were compared. After 3 months of diet regimen alone the levels of vitamin B12, folic acid and homocysteine did not show statistically (P≤0.05) significant differences. However, three months of treatment with metformin resulted in significantly higher levels of homocysteine (P=0.001) although serum levels of folic acid and vitamin B12 did not change significantly again (P=0.1 and P=0.4, respectively). Our data provided no support for this hypothesis that metformin consumption increases homoysteine secondary to folate and /or B12 deficiency.